A rare case of recurrent ovarian cancer with <em>TPM3‑NTRK1</em> gene rearrangement: A case report

Endo,Yuta; Watanabe,Takafumi; Saito,Motonobu; Saito,Katsuharu; Suzuki,Rei; Sano,Hideki; Natori,Yutaka; Sasaki,Eisaku; Ueda,Makiko; Kamo,Norihito; Furukawa,Shigenori; Soeda,Shu; Kono,Koji; Saji,Shigehira; Fujimori,Keiya

doi:10.3892/mco.2022.2523

April-2022 Volume 16 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2022 Volume 16 Issue 4

Full Size Image

Case Report Open Access

A rare case of recurrent ovarian cancer with TPM3‑NTRK1 gene rearrangement: A case report

Authors:
- Yuta Endo
- Takafumi Watanabe
- Motonobu Saito
- Katsuharu Saito
- Rei Suzuki
- Hideki Sano
- Yutaka Natori
- Eisaku Sasaki
- Makiko Ueda
- Norihito Kamo
- Shigenori Furukawa
- Shu Soeda
- Koji Kono
- Shigehira Saji
- Keiya Fujimori
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan, Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan, Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan, Department of Pediatric Oncology, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan, Department of Medical Oncology, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan

Copyright: © Endo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 90
|
Published online on: February 23, 2022

https://doi.org/10.3892/mco.2022.2523
Expand metrics +

Abstract

NTRK gene fusion is rare in gynecological cancer. Entrectinib is a novel targeted drug, which is a potent inhibitor of TRK A, B and C. The present case report described a case of recurrent ovarian cancer with TPM3‑NTRK1 rearrangement, which was detected by next‑generation sequencing (NGS) and treated with entrectinib. A 56‑year‑old woman was diagnosed as having stage IV ovarian cancer with positive pleural fluid cytology. Neoadjuvant chemotherapy and interval debulking surgery, followed by chemotherapy, were performed. A total of 10 months after completion of chemotherapy, the disease recurred and the patient was treated with multimodal therapy for recurrence. DNA‑based NGS detected TPM3‑NTRK1 rearrangement and entrectinib therapy was initiated; however, the disease progressed despite 6 weeks of entrectinib administration, and 1 month after discontinuation of entrectinib, the patient died. After their death, immunohistochemistry with a pan‑Trk monoclonal antibody was performed to determine the expression levels of TRK; however, immunohistochemistry was negative for TRK. In conclusion, the present case report described a rare case of recurrent ovarian cancer with TPM3‑NTRK1 gene fusion, in which entrectinib was not effective. While NTRK gene fusion was detected by DNA‑based NGS, immunohistochemistry was negative for TRK. These findings indicated that immunohistochemistry may be required for confirmation of TRK protein expression prior to entrectinib administration.

View Figures

View References

1	Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Chow BC, Tosi D, et al: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol. 21:271–282. 2020.PubMed/NCBI View Article : Google Scholar
2	Getalica Z, Xiu J, Swensen J and Vranic S: Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 32:147–153. 2019.PubMed/NCBI View Article : Google Scholar
3	Solomon JP, Benayed R, Hechtman JF and Ladanyi M: Identifying patients with NTRK fusion cancer. Ann Oncol. 30 (Suppl 8):viii16–viii22. 2019.PubMed/NCBI View Article : Google Scholar
4	Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, et al: NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am J Surg Pathol. 42:791–798. 2018.PubMed/NCBI View Article : Google Scholar
5	Rabban JT, Devine WP, Sangoi AR, Poder L, Alvarez E, Davis J, Rudzinski E, Garg K and Bean GR: NTRK fusion cervical sarcoma: A report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology. 77:100–111. 2020.PubMed/NCBI View Article : Google Scholar
6	Hodgson A, Pun C, Djordjevic B and Turashvili G: NTRK-rearranged cervical sarcoma: Expanding the clinicopathologic spectrum. Int J Gynecol Pathol. 40:73–77. 2021.PubMed/NCBI View Article : Google Scholar
7	Croce S, Hostein I and McCluggage WG: NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms. Genes Chromosomes Cancer. 60:147–159. 2021.PubMed/NCBI View Article : Google Scholar
8	Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M and Jungbluth AA: Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 41:1547–1551. 2017.PubMed/NCBI View Article : Google Scholar
9	Boyarskikh UA, Gulyaeva LF, Avdalyan AM, Kechin AA, Khrapov EA, Lazareva DG, Kushlinskii NE, Melkonyan A, Arakelyan A and Filipenko ML: Spectrum of TP53 mutations in BRCA1/2 associated high-grade serous ovarian cancer. Front Oncol. 10(1103)2020.PubMed/NCBI View Article : Google Scholar
10	Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F and Hong DS: Targeting TRK family proteins in cancer. Pharmacol Ther. 173:58–66. 2017.PubMed/NCBI View Article : Google Scholar
11	Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW and Davis JL: Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol. 42:927–935. 2018.PubMed/NCBI View Article : Google Scholar
12	Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, et al: NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod Pathol. 33:38–46. 2020.PubMed/NCBI View Article : Google Scholar
13	Drilon A, Leatsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele R, Farago AF, Pappo AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 378:731–739. 2018.PubMed/NCBI View Article : Google Scholar